Takeda Halts Development Of Actos Combination Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese drug maker will focus on other projects in diabetes after ending fixed-dose combination of Actos with its angiotensin receptor blocker azilsartan.
You may also be interested in...
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.